Rybelsus (semaglutide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:		
that is important for the re		lab data, to support th	 Attach any additional documentatione authorization request). Information 	
			☐ URGE	NT
MEMBER INFORMATION	ON			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:		1		
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE	ID NUMBER:			
MALE FEMALE	HEIGHT (IN/CM):	WEIGHT (LB/KG):	ALLERGIES:	
DISCLOSURE AUTHOR FOLLOWING LINK: PRI	PATIENT OR THE PRESC IZATION FORM WITH TH METHERAPEUTICS.COM ED REPRESENTATIVE (II	IIS REQUEST WHICI M/NOPP	I CAN BE FOUND AT THE	
	ENTATIVE'S PHONE NU			
PRESCRIBER INFORM	IATION			
LAST NAME:	ATION	FIRST NAME:		
		EMAIL ADDRESS:		
PRESCRIBER SPECIALTY:				
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE:	STATE: ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONTACT PERSON:		
	ICAL DISPENSING INFO	RMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:	
☐ NEW THERAPY	RENEWAL IF		HERAPY INITIATED:	
DURATION OF THERA	PY (SPECIFIC DATES):			
Continued on next page				

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 3.1.25 CAT009



Rybelsus (semaglutide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:					
1 HAS THE PATIENT TRIED ANY	OTHER MEDICATIONS FOR THIS	CONDITION?			
	NO				
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
Type II Diabetes					
	ICD-10 Code(s):				
3. REQUIRED CLINICAL INFORMATO SUPPORT A PRIOR AUTHORIA	ATION: PLEASE PROVIDE ALL REL	EVANT CLINICAL INFORMATION			
		Vos No			
is patient going to be using drug	in combination with a clinical trial?	I LI IES LINO			
Does patient have a HbA1c greater than or equal to 7% in the last 6 months or prior to starting therapy?□ Yes □ No <i>Please submit documentation.</i>					
Is the patient currently on metfor	min? □ Yes □ No <i>Please submit d</i> o	ocumentation.			
Has the patient failed treatment with, or had an intolerance to, metformin? □ Yes □ No <i>Please submit documentation.</i>					
Does the patient have an estimated GFR is less than 45 ml/min/1.73m ² ? □ Yes □ No <i>Please submit documentation.</i>					
Does the patient have advanced liver disease with cirrhosis, portal hypertension, ascites, and/or hepatic encephalopathy? No Please submit documentation.					
Has the patient tried generic liraglutide or exenatide for at least 3 months? Yes No Please submit documentation.					
Will the patient use Rybelsus(semaglutide) in combination with a DPP-4 such as Januvia, Janumet, Janumet XR, Tradjenta, Jentadueto (XR), Onglyza, Kombiglyze XR, Nesina, Kazano, Oseni, Glyxambi, Seglujan, Qtern? □ Yes □ No					
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?					
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.					



Rybelsus (semaglutide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAM	ИЕ:		
ATTESTATION: I attest the information provided is true and accurate to the understand that the Health Plan, insurer, Medical Group or its designees may request the medical information necessary to verify the accuracy of the information.	ay perform a routine audit and		
Prescriber Signature or Electronic I.D. Verification:	Date:		
CONFIDENTIALITY NOTICE: The documents accompanying this transmiss	sion contain confidential health		
information that is legally privileged. If you are not the intended recipient, yo			
disclosure, copying, distribution, or action taken in reliance on the contents	of these documents is strictly		
prohibited. If you have received this information in error, please notify the se	ender immediately (via return		
FAX) and arrange for the return or destruction of these documents.	, ·		
FAX THIS FORM TO: 800-424-7640			

O. Drime Therepouties Management Dries Authorization Dre

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP-4201

P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

